{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:22:50Z","timestamp":1773426170470,"version":"3.50.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"KidneyCAN","award":["KCRS19"],"award-info":[{"award-number":["KCRS19"]}]},{"name":"KidneyCAN","award":["EIN: 81\u20133352468"],"award-info":[{"award-number":["EIN: 81\u20133352468"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.<\/jats:p>","DOI":"10.1093\/jnci\/djaa064","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T03:39:17Z","timestamp":1587785957000},"page":"234-243","source":"Crossref","is-referenced-by-count":23,"title":["Summary From the First Kidney Cancer Research Summit, September 12\u201313, 2019: A Focus on Translational Research"],"prefix":"10.1093","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B","family":"Atkins","sequence":"additional","affiliation":[{"name":"Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5704","authenticated-orcid":false,"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria I","family":"Carlo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles G","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-2806","authenticated-orcid":false,"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Kapur","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-9247","authenticated-orcid":false,"given":"Bryan","family":"Lewis","sequence":"additional","affiliation":[{"name":"KidneyCAN, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Marston","family":"Linehan","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-2244","authenticated-orcid":false,"given":"Michael J","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-379X","authenticated-orcid":false,"given":"Kevin","family":"Pels","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-2034","authenticated-orcid":false,"given":"Susan","family":"Poteat","sequence":"additional","affiliation":[{"name":"KidneyCAN, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-0225","authenticated-orcid":false,"given":"W Kimryn","family":"Rathmell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"Nizar","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Uzzo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-4559","authenticated-orcid":false,"given":"Hans J","family":"Hammers","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"issue":"5","key":"2021030606033680900_djaa064-B1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/term.2830","article-title":"Scaffolding kidney organoids on silk","volume":"13","author":"Gupta","year":"2019","journal-title":"J Tissue Eng Regen Med"},{"issue":"12","key":"2021030606033680900_djaa064-B2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2016.10.011","article-title":"Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets","volume":"23","author":"Knezevic","year":"2016","journal-title":"Cell Chem Biol"},{"key":"2021030606033680900_djaa064-B3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ebiom.2016.10.001","article-title":"Non-NAD-Like poly(ADP-Ribose) polymerase-1 inhibitors effectively eliminate cancer in vivo","volume":"13","author":"Thomas","year":"2016","journal-title":"EBioMedicine"},{"issue":"5","key":"2021030606033680900_djaa064-B4","doi-asserted-by":"crossref","first-page":"a026468","DOI":"10.1101\/cshperspect.a026468","article-title":"Setting the stage for cancer development: SETD2 and the consequences of lost methylation","volume":"7","author":"Fahey","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"2021030606033680900_djaa064-B5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2016.07.005","article-title":"Dual chromatin and cytoskeletal remodeling by SETD2","volume":"166","author":"Park","year":"2016","journal-title":"Cell"},{"issue":"12","key":"2021030606033680900_djaa064-B6","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-17-3460","article-title":"SETD2 haploinsufficiency for microtubule methylation is an early driver of genomic instability in renal cell carcinoma","volume":"78","author":"Chiang","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"2021030606033680900_djaa064-B7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/KCA-190052","article-title":"Genomic instability in kidney cancer: etiologies and treatment opportunities","volume":"3","author":"Pili\u00e9","year":"2019","journal-title":"Kidney Cancer"},{"issue":"3","key":"2021030606033680900_djaa064-B8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"February","key":"2021030606033680900_djaa064-B9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.04.040","article-title":"Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy","volume":"458","author":"Mukalel","year":"2019","journal-title":"Cancer Lett"},{"issue":"3","key":"2021030606033680900_djaa064-B10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett"},{"key":"2021030606033680900_djaa064-B11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-4939-6646-2_22","volume-title":"Cancer Nanotechnology: Methods and Protocols","author":"Sheen","year":"2017"},{"issue":"11","key":"2021030606033680900_djaa064-B12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"2021030606033680900_djaa064-B13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","article-title":"Macropinocytosis of Nab-paclitaxel drives macrophage activation in pancreatic cancer","volume":"5","author":"Cullis","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2021030606033680900_djaa064-B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.actbio.2019.02.037","article-title":"A genetically engineered Fc-binding amphiphilic polypeptide for congregating antibodies in vivo","volume":"88","author":"Liu","year":"2019","journal-title":"Acta Biomater"},{"issue":"122","key":"2021030606033680900_djaa064-B15","first-page":"1","article-title":"A syngeneic mouse model of metastatic renal cell carcinoma for quantitative and longitudinal assessment of preclinical therapies","volume":"2017","author":"Murphy","year":"2017","journal-title":"J Vis Exp"},{"issue":"6402","key":"2021030606033680900_djaa064-B16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aat1699","article-title":"Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors","volume":"361","author":"Young","year":"2018","journal-title":"Science"},{"issue":"5","key":"2021030606033680900_djaa064-B17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nbt.4091","article-title":"Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors","volume":"36","author":"Haghverdi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2021030606033680900_djaa064-B18","first-page":"792","article-title":"A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors","author":"Slyper"},{"issue":"15","key":"2021030606033680900_djaa064-B19","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/hmg\/ddx172","article-title":"Heteroplasmic shifts in tumor mitochondrial genomes reveal tissue-specific signals of relaxed and positive selection","volume":"26","author":"Grandhi","year":"2017","journal-title":"Hum Mol Genet"},{"key":"2021030606033680900_djaa064-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.10769","article-title":"Mitochondrial DNA copy number variation across human cancers","volume":"5","author":"Reznik","year":"2016","journal-title":"Elife"},{"issue":"1","key":"2021030606033680900_djaa064-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-016-0335-7","article-title":"Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq","volume":"8","author":"Redmond","year":"2016","journal-title":"Genome Med"},{"issue":"1","key":"2021030606033680900_djaa064-B22","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.clgc.2018.10.012","article-title":"Racial and ethnic disparities in renal cell carcinoma: an analysis of clinical characteristics","volume":"17","author":"Batai","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"2021030606033680900_djaa064-B23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"issue":"5","key":"2021030606033680900_djaa064-B24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.it.2017.02.002","article-title":"PSGL-1: a new player in the immune checkpoint landscape","volume":"38","author":"Tinoco","year":"2017","journal-title":"Trends Immunol"},{"issue":"3","key":"2021030606033680900_djaa064-B25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1158\/1078-0432.CCR-15-3071","article-title":"HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status","volume":"23","author":"Cheng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2021030606033680900_djaa064-B26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"2021030606033680900_djaa064-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2021030606033680900_djaa064-B28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","article-title":"An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy","volume":"76","author":"Tavar\u00e9","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"2021030606033680900_djaa064-B29","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1158\/0008-5472.CAN-16-2953","article-title":"A PET imaging strategy to visualize activated T cells in acute graft-versus-host disease elicited by allogenic hematopoietic cell transplant","volume":"77","author":"Ronald","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"2021030606033680900_djaa064-B30","first-page":"53","article-title":"Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models","volume":"9","author":"Ehlerding","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2021030606033680900_djaa064-B31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1172\/JCI34409C1","article-title":"Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells","volume":"118","author":"Takahashi","year":"2008","journal-title":"J Clin Invest"},{"issue":"47","key":"2021030606033680900_djaa064-B32","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1038\/onc.2011.179","article-title":"Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer","volume":"30","author":"Cherkasova","year":"2011","journal-title":"Oncogene"},{"issue":"5","key":"2021030606033680900_djaa064-B33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1034\/j.1399-0039.2003.00062.x","article-title":"New allele frequency database","volume":"61","author":"Middleton","year":"2003","journal-title":"Tissue Antigens"},{"issue":"7","key":"2021030606033680900_djaa064-B34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamaoncol.2016.4419","article-title":"Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial","volume":"3","author":"Chamie","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"2021030606033680900_djaa064-B35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1042\/BST20160037","article-title":"Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells - a completed study overview","volume":"44","author":"Lamers","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"2021030606033680900_djaa064-B36","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"issue":"19","key":"2021030606033680900_djaa064-B37","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6377","key":"2021030606033680900_djaa064-B38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"6377","key":"2021030606033680900_djaa064-B39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"issue":"11","key":"2021030606033680900_djaa064-B40","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"2021030606033680900_djaa064-B41","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-18-3206","article-title":"irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial","volume":"25","author":"Pignon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2021030606033680900_djaa064-B42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"10189","key":"2021030606033680900_djaa064-B43","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"2021030606033680900_djaa064-B44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2021030606033680900_djaa064-B45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2019.37.15_suppl.101","article-title":"Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"37(15_suppl","author":"Choueiri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021030606033680900_djaa064-B46","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021030606033680900_djaa064-B47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"2021030606033680900_djaa064-B48","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2019.37.15_suppl.4569","article-title":"KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced non\u2012clear cell renal cell carcinoma (NCC-RCC)","volume":"37(15_suppl","author":"Lee","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021030606033680900_djaa064-B49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2017.09.044","article-title":"FLCN: the causative gene for Birt-Hogg-Dub\u00e9 syndrome","volume":"640","author":"Schmidt","year":"2018","journal-title":"Gene"},{"issue":"1","key":"2021030606033680900_djaa064-B50","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12037","article-title":"The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding","volume":"7","author":"Woodford","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"2021030606033680900_djaa064-B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"issue":"27","key":"2021030606033680900_djaa064-B52","doi-asserted-by":"crossref","first-page":"E6274","DOI":"10.1073\/pnas.1710849115","article-title":"Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma","volume":"115","author":"Priolo","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2021030606033680900_djaa064-B53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.2017.020909","article-title":"Renal medullary carcinoma: establishing standards in practice","volume":"13","author":"Beckermann","year":"2017","journal-title":"J Oncol Pract"},{"issue":"9","key":"2021030606033680900_djaa064-B54","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-17-3296","article-title":"A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma","volume":"24","author":"Msaouel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2021030606033680900_djaa064-B55","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-18-0269","article-title":"Therapeutic targeting of TFE3\/IRS-1\/PI3K\/mTOR axis in translocation renal cell carcinoma","volume":"24","author":"Damayanti","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2021030606033680900_djaa064-B56","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","article-title":"TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease","volume":"17","author":"Baba","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2021030606033680900_djaa064-B57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaa064\/33750563\/djaa064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/113\/3\/234\/36419095\/djaa064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/113\/3\/234\/36419095\/djaa064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T06:11:59Z","timestamp":1615011119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/113\/3\/234\/5828225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,5,2]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaa064","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,5,2]]}}}